PT Saptausaha Gemilangindah Tbk (SAGE)
Jul 31, 2025 - SAGE was delisted (reason: acquired by SUPN)
8.68
-0.02 (-0.23%)
Inactive · Last trade price
on Jul 30, 2025
Sage Therapeutics Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 9,430 | 16,895 | 21,963 | 35,610 | 26,009 | 3,478 | Upgrade
|
| Revenue Growth (YoY) | -49.71% | -23.08% | -38.32% | 36.91% | 647.83% | 949.99% | Upgrade
|
| Cost of Revenue | 4,596 | 8,279 | 10,162 | 16,420 | 13,525 | 1,860 | Upgrade
|
| Gross Profit | 4,834 | 8,616 | 11,801 | 19,190 | 12,484 | 1,618 | Upgrade
|
| Selling, General & Admin | 6,755 | 7,274 | 5,812 | 5,717 | 6,196 | 4,509 | Upgrade
|
| Other Operating Expenses | 217.63 | 283.55 | 196.9 | 170.9 | 56.98 | 79.01 | Upgrade
|
| Operating Expenses | 7,314 | 7,831 | 6,104 | 5,932 | 6,334 | 4,675 | Upgrade
|
| Operating Income | -2,480 | 784.16 | 5,697 | 13,258 | 6,150 | -3,057 | Upgrade
|
| Interest Expense | - | - | - | - | - | -1.89 | Upgrade
|
| Interest & Investment Income | 7.75 | 10.26 | 6.95 | 1.19 | 4.97 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -417.7 | -275.17 | -342.13 | -89.18 | -36.9 | -87.34 | Upgrade
|
| EBT Excluding Unusual Items | -2,890 | 519.25 | 5,362 | 13,170 | 6,118 | -3,147 | Upgrade
|
| Other Unusual Items | - | - | - | -493.1 | -495.76 | 131.08 | Upgrade
|
| Pretax Income | -2,890 | 519.25 | 5,362 | 12,677 | 5,623 | -3,015 | Upgrade
|
| Income Tax Expense | 251.76 | 446.15 | 589.28 | 973.72 | 743.25 | 122.29 | Upgrade
|
| Earnings From Continuing Operations | -3,142 | 73.1 | 4,772 | 11,703 | 4,879 | -3,138 | Upgrade
|
| Minority Interest in Earnings | 3.9 | 4.18 | -0.89 | -0.3 | - | - | Upgrade
|
| Net Income | -3,138 | 77.28 | 4,772 | 11,703 | 4,879 | -3,138 | Upgrade
|
| Net Income to Common | -3,138 | 77.28 | 4,772 | 11,703 | 4,879 | -3,138 | Upgrade
|
| Net Income Growth | - | -98.38% | -59.23% | 139.84% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 8,033 | 8,033 | 8,033 | 6,423 | 6,423 | 2,290 | Upgrade
|
| Shares Outstanding (Diluted) | 8,033 | 8,033 | 8,033 | 6,423 | 6,423 | 2,290 | Upgrade
|
| Shares Change (YoY) | -12.62% | - | 25.06% | - | 180.45% | 281.98% | Upgrade
|
| EPS (Basic) | -0.39 | 0.01 | 0.59 | 1.82 | 0.76 | -1.37 | Upgrade
|
| EPS (Diluted) | -0.39 | 0.01 | 0.59 | 1.82 | 0.76 | -1.37 | Upgrade
|
| EPS Growth | - | -98.38% | -67.40% | 139.84% | - | - | Upgrade
|
| Gross Margin | 51.26% | 51.00% | 53.73% | 53.89% | 48.00% | 46.52% | Upgrade
|
| Operating Margin | -26.30% | 4.64% | 25.94% | 37.23% | 23.65% | -87.91% | Upgrade
|
| Profit Margin | -33.27% | 0.46% | 21.73% | 32.86% | 18.76% | -90.22% | Upgrade
|
| EBITDA | -2,138 | 1,058 | 5,792 | 13,302 | 6,232 | -2,970 | Upgrade
|
| EBITDA Margin | -22.68% | 6.26% | 26.37% | 37.36% | 23.96% | -85.39% | Upgrade
|
| D&A For EBITDA | 341.65 | 274.02 | 95.35 | 44.36 | 81.25 | 87.58 | Upgrade
|
| EBIT | -2,480 | 784.16 | 5,697 | 13,258 | 6,150 | -3,057 | Upgrade
|
| EBIT Margin | -26.30% | 4.64% | 25.94% | 37.23% | 23.65% | -87.91% | Upgrade
|
| Effective Tax Rate | - | 85.92% | 10.99% | 7.68% | 13.22% | - | Upgrade
|
| Advertising Expenses | - | 1,768 | 369.42 | 2,318 | 3,084 | 1,562 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.